In Agreement For AI-Augmented Screening Platform To Expand Research Capabilities.

Georgia has entered into a licensing agreement for the use of  X Ligand Express (Cloud-Based proteome screening platform called Ligand Express) a cloud-based in silico proteome screening platform.

Ligand Express (Cloud-Based proteome screening platform called Ligand Express) is a structure-based and Artificial Intelligence (AI) augmented proteome screening platform that is being used to uncover novel targets that are modeled to interact with a small molecule.

The year-long agreement will enable to quickly and efficiently elucidate mechanisms of action, evaluate safety profiles and explore additional applications for a number of its investigational small molecules including those identified in highly disease-relevant phenotypic screens.

Traditional development of small molecule therapies focuses on specific disease-associated protein targets. However once a drug enters the body it interacts with dozens if not hundreds of proteins before it is eliminated from the body.

With Ligand Express (Cloud-Based proteome screening platform called Ligand Express) it is possible to capture a unique panoramic view of the proteome for a given small molecule. As the technology can model the ways in which a small molecule will interact with all proteins (of known structure) it can help identify both ‘on-targets’ (interactions that may have a desirable effect on a certain disease) as well as ‘off-targets’ (interactions that may cause an adverse effect).